ClinicalTrials.gg
CompletedNCT01529112Updated Sep 26, 2017Results posted

A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

A Phase 2 interventional study of Lenvatinib and Lenvatinib matched placebo in Non-Small Cell Lung Cancer, sponsored by Eisai Inc.. Completed at 50 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-26.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung — 3 open to participants now, 4 under way, 1 of them phase 3. lenvatinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
3rd of 14
135 · median 29
Started
2011
the only one that year
Phase 2
8 of 14
2 open now
Registered
2nd of 14
by date
Lead sponsor
2 of 14
Eisai Inc.

Among the 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung, this one is the 3rd largest by enrollment, is the only one that started in 2011, is one of 8 in phase 2, and was the 2nd registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to compare the overall survival of patients receiving E7080 + Best Supportive Care (BSC) with those receiving placebo + Best Supportive Care.

Read the detailed description

This double-blind, placebo-controlled, multicenter, randomized Phase II study will consist of a 2-arm design, comparing E7080 + BSC (Arm 1) with placebo + BSC (Arm 2). Participants will be randomized in the ratio of 2:1 to receive either E7080 or placebo in a blinded manner.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Locally Advanced
  • Metastatic Non-Squamous Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age greater than or equal to 18 years;
  2. Participants with or cytologically confirmed non-squamous NSCLC with locally advanced or disease based on Tumor, Node, Metastasis (TNM) staging according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, Seventh Edition, who had failed at least two lines of systemic anticancer therapy for advanced or metastatic NSCLC (did not include chemotherapy). In countries where erlotinib was approved and marketed for the treatment of NSCLC, participants must have received erlotinib treatment (or gefitinib for participants outside of the US) for their NSCLC if they had known EGFR-activating mutations. Participants of unknown EGFR status who had not received prior erlotinib (or gefitinib) should have been tested for EGFR-activating mutations prior to study entry. In countries where crizotinib was approved and marketed, participants must have received crizotinib treatment for NSCLC that was ALK-positive. Participants with ALK positive NCSLC or participants with KRAS mutations were not required to have prior treatment with erlotinib or gefitinib
  3. Participants must have at least 1 site of by the version 1.1 (RECIST v.1.1);
  4. PS of 0 to 2;
  5. Participants must have adequate renal function as evidenced by serum creatinine less than or equal to 1.5 x (ULN) or calculated greater than or equal to 30 mL/min per the Cockcroft and Gault formula;
  6. Blood pressure must be well-controlled (less than or equal to140/90 mm Hg at Screening) with or without antihypertensive medication. Participants must have no history of hypertensive crisis or hypertensive encephalopathy;
  7. Participants must have adequate bone marrow function as evidenced by (ANC) greater than or equal to 1.5 x 109/L, greater than or equal to 9.0 g/dL, and count greater than or equal to 100 x 109/L;
  8. Participants must have adequate liver function as evidenced by less than or equal to 1.5 times the ULN, and alkaline phosphatase, (ALT), and aspartate aminotransferase (AST) less than or equal to 3 x ULN (in the case of liver metastases, less than or equal to 5 x ULN).
  9. Participants must have adequate coagulation system function as defined by /International normalized ratio (INR) less than or equal to 1.5 x ULN.
  10. Male or female participants of child-producing potential must agree to use double barrier , oral contraceptives, or avoidance of pregnancy measures during the study and for 90 days after the last day of treatment;
  11. Females of must have a negative serum pregnancy test;
  12. Females may not be breastfeeding;
  13. Ability to understand and willingness to sign a written .

Exclusion criteria

Exclusion Criteria

  1. Prior therapy with E7080 or other small molecule vascular endothelial growth factor inhibitors;
  2. Presence of , unless the participant has received adequate treatment at least 4 weeks prior to randomization, and is stable, asymptomatic, and off for at least 4 weeks prior to randomization;
  3. Meningeal carcinomatosis;
  4. Received chemotherapy, targeted therapy, radiotherapy, surgery, or immunotherapy within the 21 days prior to commencing study treatment or have not recovered from all treatment-related toxicities to Grade less than or equal to 2, except for alopecia;
  5. Received treatment with another agent within the 30 days prior to commencing study treatment or participants who have not recovered from side effects of an investigational drug to Grade less than or equal to 2, except for alopecia;
  6. Participants with proteinuria greater than 1+ on urine dipstick testing will undergo 24-hour urine collection for quantitative assessment of proteinuria. Participants with 24-hour urine protein greater than or equal to 1 g/24 hours will be ineligible;
  7. Serious non-healing wound, ulcer, bone fracture, or have undergone a major surgical procedure, open , or significant traumatic injury within the 28 days prior to commencing study treatment.
  8. Major surgery scheduled during the projected course of the study;
  9. History of bleeding diathesis or coagulopathy;
  10. Active hemoptysis (defined as bright red blood of a half teaspoon or more) within the 30 days prior to study entry;
  11. nausea and vomiting, malabsorption, significant bowel resection, or any other medical condition that would preclude adequate absorption or result in the inability to take oral medication;
  12. Other within 3 years of randomization, with the exception of adequately treated carcinoma in situ of the cervix or non-melanoma skin cancer, with no subsequent evidence of recurrence and/or malignancies diagnosed at a stage where definitive therapy results in near certain cures.
  13. Significant cardiovascular impairment (history of congestive heart failure [NYHA] Class greater than II, unstable angina or myocardial infarction within the past 6 months, or serious cardiac arrhythmia);
  14. Any history of cerebral vascular accident (CVA), (TIA), or Grade greater than or equal to 2 peripheral vascular disease unless they have had no evidence of active disease for at least 6 months prior to randomization;
  15. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the 6 months prior to enrollment;
  16. Participants with organ allografts requiring ;
  17. Known positive (HIV), known surface antigen, or positive;
  18. to E7080 or any of the ;
  19. Any history of or concomitant medical condition that, in the opinion of the Investigator, would compromise the participant's ability to safely complete the study.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Lenvatinib

    Participants received lenvatinib 24 mg orally, once daily continuously in each 28-day treatment cycle plus Best Supportive Care (BSC)

    Drug: Lenvatinib · Drug: BSC

  • Placebo comparator
    Lenvatinib matched placebo

    Participants received lenvatinib matched placebo orally, once daily continuously in each 28-day treatment cycle plus BSC

    Drug: Lenvatinib matched placebo · Drug: BSC

Interventions

  • Also known as: E7080

  • DrugLenvatinib matched placebo
  • DrugBSC
06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of randomization until the date of death from any cause.

    Time frame: From date of randomization (Day 1) until occurrence of 90 deaths in the study (cut off date 26 November 2013), approximately 22 months

Secondary outcomes

  1. Number of Participants With Treatment Emergent Non-serious Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs)

    An AE was defined as any untoward medical occurrence in a clinical investigation participant administered with an investigational product. A SAE was defined as any untoward medical occurrence that at any dose; resulted in death, was life-threatening (i.e., the subject was at a risk of death at the time of the event; this did not include an event that hypothetically might have caused death if it had been more severe), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, or was a congenital abnormality/birth defect. In this study, treatment emergent adverse events (TEAEs) (defined as an AE (serious/non-serious) that started/increased in severity on/after the first dose of study medication up to 30 days after the final dose of study medication) were assessed.

    Time frame: For each participant, from the first dose till 30 days after the last dose or up to approximately 2 years (data cut-off date of 21 January 2014)

  2. 6-Month Survival Rate

    Event-free survival rate was calculated using Kaplan Meier estimations. The percentage of participants with event free survival up to 6 months and the corresponding 95% confidence interval were estimated for each treatment group. The data presented is based on the data cut-off date of 26 November 2013 while the study is still ongoing.

    Time frame: From date of randomization (Day 1) up to 6 months

  3. 1-year Survival Rate

    Event-free survival rate was calculated using Kaplan Meier estimations. The percentage of participants with event free survival up to 1 year and the corresponding 95% confidence interval were estimated for each treatment group. The data presented is based on the data cut-off date of 26 November 2013 while the study is still ongoing.

    Time frame: From date of randomization (Day 1) up to 1 year

  4. Progression-Free Survival (PFS)

    PFS was defined as the time from the date of the randomization until the date of first documented disease progression according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 or date of death from any cause (whichever occurred first), assessed based on investigator's assessment. Disease progression per RECIST v1.1 was defined as at least a 20% relative increase and 5 mm absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions. The data presented is based on the data cut-off date of 21 January 2014 while the study is still ongoing.

    Time frame: From date of randomization (Day 1) until date of first documentation of disease progression or death from any cause (whichever occurred first) or up to approximately 2 years (data cut-off date of 21 January 2014)

  5. Overall Response Rate (ORR)

    ORR, defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as determined by investigator using RECIST 1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR = CR + PR. The data presented is based on the data cut-off date of 21 January 2014 while the study is still ongoing.

    Time frame: From date of randomization (Day 1) until disease progression or death, development of unacceptable toxicity, withdrawal of consent, withdrawal by Investigator, or up to approximately 2 years (data cut-off date of 21 January 2014)

  6. Response Duration (RD)

    Response duration, defined as the time from the date of the first assessment demonstrating a CR or PR to the date of the first assessment demonstrating progressive disease or death, whichever occurred first. This is an investigator assessed outcome, measured using RECIST 1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Response duration was summarized by including only subjects with events. The data presented is based on the data cut-off date of 21 January 2014 while the study is still ongoing.

    Time frame: From date of randomization (Day 1) until disease progression or death, development of unacceptable toxicity, withdrawal of consent, withdrawal by Investigator, or up to approximately 2 years (data cut-off date of 21 January 2014)

  7. Disease Control Rate (DCR)

    The percentage of participants with CR, PR, or stable disease (SD) for greater than or equal to 12 weeks. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable disease was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on the study. The data presented is based on the data cut-off date of 21 January 2014 while the study is still ongoing.

    Time frame: From date of randomization (Day 1) until disease progression or death, development of unacceptable toxicity, withdrawal of consent, withdrawal by Investigator, or up to approximately 2 years (data cut-off date of 21 January 2014)

  8. The Percentage of Participants With The European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Symptom Scores Achieving Clinically Significant Deterioration on Quality of Life (QOL)

    The EORTC QLQ-C30 symptom score, a cancer specific self-reporting questionnaire was composed of 9-symptom scales assessing fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties. All of the multi-item scales and single-item measures ranged in score from 0 to 100. For each domain and item, a linear transformation was applied to standardize the raw score to a range from 0 to 100, with a higher scale score representing a higher response level/ high level of symptomatology / problems. The data is presented as percentage of participants with EORTC QLQ-C30 symptom score achieving clinically significant deterioration on QOL. Participants were considered as deteriorated for a given symptom if the change in score from Baseline was 10 points or higher at any time point after Baseline. The data presented is based on the data cut-off date of 21 January 2014 while the study is still ongoing.

    Time frame: Baseline (Day 1 of Cycle 1 (prior to treatment in Cycle 1)), every 4 weeks during treatment, and 4 weeks after completing treatment or up to approximately 2 years (data cut-off date of 21 January 2014)

  9. The Percentage of Participants With The European Organization for Research and Treatment of Cancer (EORTC) Module QLQ-LC13 (Lung Cancer 13) Symptom Scores Achieving Clinically Significant Deterioration on QOL

    The EORTC module QLQ-LC13 symptom score was a self-reporting cancer-specific questionnaire composed of 13 questions incorporated into 1 multi-item scale designed to evaluate dyspnea and a series of single items assessing different types of pain, as well as, cough, hemoptysis, dysphagia, sore mouth, alopecia, and peripheral neuropathy. For each domain and item, a linear transformation was applied to standardize the raw score to a range from 0 to 100, with 100 representing the best possible function/QOL, and highest burden of symptoms for symptom domains and single items. The data is presented as percentage of participants with EORTC module QLQ-C13 symptom score achieving clinically significant deterioration on QOL. Participants were considered as deteriorated for a given symptom if the change in score from Baseline was 10 points or higher at any time point after Baseline. The data presented is based on the data cut-off date of 21 January 2014 while the study is still ongoing.

    Time frame: Baseline (Day 1 of Cycle 1 (prior to treatment in Cycle 1)), every 4 weeks during treatment, and 4 weeks after completing treatment or up to approximately 2 years (data cut-off date of 21 January 2014)

  10. Pharmacokinetic (PK) Profile of Lenvatinib in Subjects With Non Small Cell Lung Cancer (NSCLC)

    Blood samples were collected for lenvatinib PK analysis. Lenvatinib concentrations from sparse PK sampling were measured. The data is presented as mean nanograms per milliliter +/- Standard deviation of lenvatinib serum concentration.

    Time frame: Cycle 1/Day 1 (between 0.5 and 4 hours postdose and 6 and 10 hours postdose), Cycle 1/Day 15 (predose, between 0.5 and 4 hours postdose, and 6 and 10 hours postdose), and Day 1 of Cycles 2 though 4 (predose and between 2 and 12 hours postdose)

07

Results

Posted Feb 18, 2016

Participant flow

Participant flow — Overall Study
MilestoneLenvatinibLenvatinib Matched Placebo
Started8946
Completed205
Not completed6941
Withdrew: Adverse event20
Withdrew: Death5938
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject73

Outcome measures

SecondaryNumber of Participants With Treatment Emergent Non-serious Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs)

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered with an investigational product. A SAE was defined as any untoward medical occurrence that at any dose; resulted in death, was life-threatening (i.e., the subject was at a risk of death at the time of the event; this did not include an event that hypothetically might have caused death if it had been more severe), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, or was a congenital abnormality/birth defect. In this study, treatment emergent adverse events (TEAEs) (defined as an AE (serious/non-serious) that started/increased in severity on/after the first dose of study medication up to 30 days after the final dose of study medication) were assessed.

Time frame:
For each participant, from the first dose till 30 days after the last dose or up to approximately 2 years (data cut-off date of 21 January 2014)
Reported as:
Number · Participants
Number of Participants With Treatment Emergent Non-serious Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs)
ParticipantsLenvatinibLenvatinib Matched Placebo
Treatment Emergent Non-Serious AEs8342
Treatment Emergent SAEs4621
Secondary6-Month Survival Rate

Event-free survival rate was calculated using Kaplan Meier estimations. The percentage of participants with event free survival up to 6 months and the corresponding 95% confidence interval were estimated for each treatment group. The data presented is based on the data cut-off date of 26 November 2013 while the study is still ongoing.

Time frame:
From date of randomization (Day 1) up to 6 months
Reported as:
Number · Percentage of Participants
6-Month Survival Rate
Percentage of ParticipantsLenvatinibLenvatinib Matched Placebo
6-Month Survival Rate61.6 (50.24 to 71.1)49 (33.49 to 62.8)
Secondary1-year Survival Rate

Event-free survival rate was calculated using Kaplan Meier estimations. The percentage of participants with event free survival up to 1 year and the corresponding 95% confidence interval were estimated for each treatment group. The data presented is based on the data cut-off date of 26 November 2013 while the study is still ongoing.

Time frame:
From date of randomization (Day 1) up to 1 year
Reported as:
Number · Percentage of Participants
1-year Survival Rate
Percentage of ParticipantsLenvatinibLenvatinib Matched Placebo
1-year Survival Rate35.8 (25.13 to 46.54)20.5 (9.96 to 33.74)
SecondaryProgression-Free Survival (PFS)

PFS was defined as the time from the date of the randomization until the date of first documented disease progression according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 or date of death from any cause (whichever occurred first), assessed based on investigator's assessment. Disease progression per RECIST v1.1 was defined as at least a 20% relative increase and 5 mm absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions. The data presented is based on the data cut-off date of 21 January 2014 while the study is still ongoing.

Time frame:
From date of randomization (Day 1) until date of first documentation of disease progression or death from any cause (whichever occurred first) or up to approximately 2 years (data cut-off date of 21 January 2014)
Reported as:
Median · weeks
Progression-Free Survival (PFS)
weeksLenvatinibLenvatinib Matched Placebo
Progression-Free Survival (PFS)20.9 (15.86 to 23.86)7.9 (7.43 to 8.14)
SecondaryOverall Response Rate (ORR)

ORR, defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as determined by investigator using RECIST 1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR = CR + PR. The data presented is based on the data cut-off date of 21 January 2014 while the study is still ongoing.

Time frame:
From date of randomization (Day 1) until disease progression or death, development of unacceptable toxicity, withdrawal of consent, withdrawal by Investigator, or up to approximately 2 years (data cut-off date of 21 January 2014)
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR)
Percentage of ParticipantsLenvatinibLenvatinib Matched Placebo
Overall Response Rate (ORR)10.1 (4.7 to 18.3)2.2 (0.1 to 11.5)
PrimaryOverall Survival (OS)

OS was defined as the time from the date of randomization until the date of death from any cause.

Time frame:
From date of randomization (Day 1) until occurrence of 90 deaths in the study (cut off date 26 November 2013), approximately 22 months
Reported as:
Median · weeks
Overall Survival (OS)
weeksLenvatinibLenvatinib Matched Placebo
Overall Survival (OS)38.4 (26.57 to 47.86)24.1 (15.29 to 36.43)
SecondaryResponse Duration (RD)

Response duration, defined as the time from the date of the first assessment demonstrating a CR or PR to the date of the first assessment demonstrating progressive disease or death, whichever occurred first. This is an investigator assessed outcome, measured using RECIST 1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Response duration was summarized by including only subjects with events. The data presented is based on the data cut-off date of 21 January 2014 while the study is still ongoing.

Time frame:
From date of randomization (Day 1) until disease progression or death, development of unacceptable toxicity, withdrawal of consent, withdrawal by Investigator, or up to approximately 2 years (data cut-off date of 21 January 2014)
Reported as:
Median · Weeks
Response Duration (RD)
WeeksLenvatinibLenvatinib Matched Placebo
Response Duration (RD)24.2 (12.71 to 33.14)43.3 (NA to NA)
SecondaryDisease Control Rate (DCR)

The percentage of participants with CR, PR, or stable disease (SD) for greater than or equal to 12 weeks. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable disease was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on the study. The data presented is based on the data cut-off date of 21 January 2014 while the study is still ongoing.

Time frame:
From date of randomization (Day 1) until disease progression or death, development of unacceptable toxicity, withdrawal of consent, withdrawal by Investigator, or up to approximately 2 years (data cut-off date of 21 January 2014)
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR)
Percentage of ParticipantsLenvatinibLenvatinib Matched Placebo
Disease Control Rate (DCR)42.7 (32.3 to 53.6)19.6 (9.4 to 33.9)
SecondaryThe Percentage of Participants With The European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Symptom Scores Achieving Clinically Significant Deterioration on Quality of Life (QOL)

The EORTC QLQ-C30 symptom score, a cancer specific self-reporting questionnaire was composed of 9-symptom scales assessing fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties. All of the multi-item scales and single-item measures ranged in score from 0 to 100. For each domain and item, a linear transformation was applied to standardize the raw score to a range from 0 to 100, with a higher scale score representing a higher response level/ high level of symptomatology / problems. The data is presented as percentage of participants with EORTC QLQ-C30 symptom score achieving clinically significant deterioration on QOL. Participants were considered as deteriorated for a given symptom if the change in score from Baseline was 10 points or higher at any time point after Baseline. The data presented is based on the data cut-off date of 21 January 2014 while the study is still ongoing.

Time frame:
Baseline (Day 1 of Cycle 1 (prior to treatment in Cycle 1)), every 4 weeks during treatment, and 4 weeks after completing treatment or up to approximately 2 years (data cut-off date of 21 January 2014)
Reported as:
Number · Percentage of participants
The Percentage of Participants With The European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Symptom Scores Achieving Clinically Significant Deterioration on Quality of Life (QOL)
Percentage of participantsLenvatinibLenvatinib Matched Placebo
Appetite Loss (N=82, 39)59.866.7
Constipation (N=82, 40)43.952.5
Diarrhea (N=81, 40)48.117.5
Dyspnea (N=82, 40)43.947.5
Insomnia (N=82, 40)53.735
Nausea and Vomiting (N=82, 40)46.340
Pain (N= 82, 40)74.465
Fatigue (N= 82, 40)63.467.5
Financial Difficulties (N= 81, 40)34.630
SecondaryThe Percentage of Participants With The European Organization for Research and Treatment of Cancer (EORTC) Module QLQ-LC13 (Lung Cancer 13) Symptom Scores Achieving Clinically Significant Deterioration on QOL

The EORTC module QLQ-LC13 symptom score was a self-reporting cancer-specific questionnaire composed of 13 questions incorporated into 1 multi-item scale designed to evaluate dyspnea and a series of single items assessing different types of pain, as well as, cough, hemoptysis, dysphagia, sore mouth, alopecia, and peripheral neuropathy. For each domain and item, a linear transformation was applied to standardize the raw score to a range from 0 to 100, with 100 representing the best possible function/QOL, and highest burden of symptoms for symptom domains and single items. The data is presented as percentage of participants with EORTC module QLQ-C13 symptom score achieving clinically significant deterioration on QOL. Participants were considered as deteriorated for a given symptom if the change in score from Baseline was 10 points or higher at any time point after Baseline. The data presented is based on the data cut-off date of 21 January 2014 while the study is still ongoing.

Time frame:
Baseline (Day 1 of Cycle 1 (prior to treatment in Cycle 1)), every 4 weeks during treatment, and 4 weeks after completing treatment or up to approximately 2 years (data cut-off date of 21 January 2014)
Reported as:
Number · Percentage of participants
The Percentage of Participants With The European Organization for Research and Treatment of Cancer (EORTC) Module QLQ-LC13 (Lung Cancer 13) Symptom Scores Achieving Clinically Significant Deterioration on QOL
Percentage of participantsLenvatinibLenvatinib Matched Placebo
Alopecia (Hair Loss) (N= 80, 39)16.315.4
Dysphagia (Trouble Swallowing) (N= 80, 39)43.823.1
Haemoptysis (Coughing Up Blood) (N=80, 39)1510.3
How Much Cough (N=80, 39)33.828.2
Medicine For Pain (N=43, 21)41.928.6
Pain In Arm Or Shoulder (N=80, 39)5543.6
Pain In Chest (N=80, 39)37.528.2
Pain In Other Parts Of Body (N=79, 39)51.938.5
Peripheral Neuropathy-Tingling Hands/Feet(N=80,39)36.341
Short Of Breath When Climbed Stairs (N=80, 39)4546.2
Short Of Breath When Rested (N=80, 39)36.341
Short Of Breath When Walked (N=80, 39)4551.3
Sore Mouth Or Tongue (N=80, 39)605.1
SecondaryPharmacokinetic (PK) Profile of Lenvatinib in Subjects With Non Small Cell Lung Cancer (NSCLC)

Blood samples were collected for lenvatinib PK analysis. Lenvatinib concentrations from sparse PK sampling were measured. The data is presented as mean nanograms per milliliter +/- Standard deviation of lenvatinib serum concentration.

Time frame:
Cycle 1/Day 1 (between 0.5 and 4 hours postdose and 6 and 10 hours postdose), Cycle 1/Day 15 (predose, between 0.5 and 4 hours postdose, and 6 and 10 hours postdose), and Day 1 of Cycles 2 though 4 (predose and between 2 and 12 hours postdose)
Reported as:
Mean · nanograms per milliliter
Pharmacokinetic (PK) Profile of Lenvatinib in Subjects With Non Small Cell Lung Cancer (NSCLC)
nanograms per milliliterLenvatinib
Cycle 1 Day 1 (0.5 to 4 hours postdose); N=4793.4 ± 125.66
Cycle 1 Day 1 (6 to 10 hours postdose); N=46229.0 ± 114.06
Cycle 1 Day 15 (Pre-dose); N=4377.8 ± 84.73
Cycle 1 Day 15 (0.5 to 4 hours postdose); N=44134.3 ± 119.44
Cycle 1 Day 15 (6 to 10 hours postdose); N=39230.7 ± 106.29
Cycle 2 Day 1 (Pre-dose); N=4268.6 ± 73.53
Cycle 2 Day 1 (2 to 12 hours postdose); N=41260.4 ± 176.26
Cycle 3 Day 1 (Pre-dose); N=3453.5 ± 49.20
Cycle 3 Day 1 (2 to 12 hours postdose); N=31255.3 ± 173.79
Cycle 4 Day 1 (Pre-dose); N=2946.2 ± 34.94
Cycle 4 Day 1 (2 to 12 hours postdose); N=27217.7 ± 167.70

Adverse events

Collected over For each participant, from the first dose till 30 days after the last dose or up to approximately 2 years (data cut-off date of 21 January 2014). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenvatinib—46/89 (51.7%)83/89 (93.3%)
Lenvatinib Matched Placebo—21/46 (45.7%)42/46 (91.3%)
Most frequent serious events
Showing 10 of 57
Most frequent serious events
EventLenvatinibLenvatinib Matched Placebo
DYSPNOEARespiratory, thoracic and mediastinal disorders7/894/46
PNEUMONIAInfections and infestations7/893/46
GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders4/893/46
CHEST PAINGeneral disorders3/891/46
HAEMOPTYSISRespiratory, thoracic and mediastinal disorders3/891/46
PNEUMOTHORAXRespiratory, thoracic and mediastinal disorders3/891/46
STOMATITISGastrointestinal disorders2/890/46
ASTHENIAGeneral disorders2/890/46
PERFORMANCE STATUS DECREASEDGeneral disorders2/890/46
LOWER RESPIRATORY TRACT INFECTIONInfections and infestations2/891/46
Most frequent other events
Showing 10 of 46
Most frequent other events
EventLenvatinibLenvatinib Matched Placebo
HYPERTENSIONVascular disorders40/894/46
PROTEINURIARenal and urinary disorders33/893/46
DECREASED APPETITEMetabolism and nutrition disorders31/8911/46
DIARRHOEAGastrointestinal disorders27/893/46
STOMATITISGastrointestinal disorders27/894/46
NAUSEAGastrointestinal disorders26/896/46
FATIGUEGeneral disorders24/898/46
VOMITINGGastrointestinal disorders23/893/46
COUGHRespiratory, thoracic and mediastinal disorders16/8910/46
DYSPHONIARespiratory, thoracic and mediastinal disorders19/890/46

Baseline characteristics

Age, Continuous
Age, Continuous(Years)LenvatinibLenvatinib Matched PlaceboTotal
Median63 (41 to 82)63.5 (44 to 77)63 (41 to 82)
Sex: Female, Male
Sex: Female, Male(Participants)LenvatinibLenvatinib Matched PlaceboTotal
Female441963
Male452772
08

Study locations

50 sites
  • Donald W. Hill, M.D., F.A.C.P.
    Casa Grande, Arizona 85122, United States
  • Arizona Oncology Associates , PC - HOPE
    Tucson, Arizona 85710, United States
  • Ronald Yanagihara, MD 9360 North Name Uno Suite 130 Gilroy California 95020
    Gilroy, California 95020, United States
  • Ocala Oncology Center, P.L.
    Ocala, Florida 34471, United States
  • Washington University 660 South Euclid Avenue Campus Box 8124 St Louis Missouri 63110
    Saint Louis, Missouri 63110, United States
  • New York Oncology Heamatology - Latham
    Clifton Park, New York 12065, United States
  • Montefiore Medical Park 1695 Easchester Road Floor 1 Bronx, NY 10461
    New York, New York 10467, United States
  • Cancer Treatment and Research Centre Bismarck North Dakota 58501
    Bismarck, North Dakota 58501, United States
  • Texas Oncology, P.A. - Paris
    Paris, Texas 75460, United States
  • Texas Oncology, P.A. - Plano
    Plano, Texas 75093, United States
  • Texas Oncology, P.A. - Waco
    Waco, Texas 76712, United States
  • OLV Ziekenhuis
    Aalst, 9300, Belgium
  • Grand Hopital de Charleroi
    Charleroi, 6000, Belgium
  • AZ Sint-Maarten
    Duffel, 2570, Belgium
  • UZ Antwerpen
    Edegem, 2650, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • C. H. R. de la Citadelle
    Liege, 4000, Belgium
  • Domaine Universitaire du Sart-Tilman
    Liege, 4000, Belgium
  • Institut onkologie a rehabilitace Na Plesi
    Nova Ves pod Plesi, Czechia
  • Avicennus, s.r.o.
    Nymburk, Czechia
  • Fakultni nemocnice Na Bulovce
    Praha 8, Czechia
  • Oblastni nemocnice Pribram, a.s.
    Pribram, Czechia
  • Semmelweis Egyetem AOK
    Budapest, 1125, Hungary
  • Orszagos Koranyi TBC es Pulmonologiai Intezet
    Budapest, 1529, Hungary
  • Matrai Gyogyintezet
    Matrahaza, 3233, Hungary
  • Fejer Megyei Szent Gyorgy Korhaz
    Szekesfehervar, 8000, Hungary
  • Komarom-Esztergom Megyei Onkorm. Szent Borbala Korhaza
    Tatabanya, 2800, Hungary
  • Tudogyogyintezet Torokbalint
    Torokbalint, 2045, Hungary
  • Zala Megyei Korhaz
    Zalaegerszeg, 8900, Hungary
  • Azienda Ospedaliera G. Rummo
    Benevento, 82100, Italy
  • Azienda Ospedaliero Universitaria San Martino
    Genova, 16132, Italy
  • Azienda Ospedaliera San Gerardo
    Milano, 20052, Italy
  • Istituto Clinico Humanitas
    Milano, 20089, Italy
  • Azienda Ospedaliera Universitaria di Parma
    Parma, 43100, Italy
  • Fondazione Salvatore Maugeri IRCCS
    Pavia, 27100, Italy
  • Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia
    Perugia, 6156, Italy
  • Azienda Ospedaliera San Camillo Forlanini
    Roma, 149, Italy
  • Ospedale Mater Salutis
    Verona, 37045, Italy
  • Chungbuk National University Hospital
    Chungcheongbuk-do, Korea, Republic of
  • Chonnam National University Hwasun Hospital
    Hwasun-gun, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam-si, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, Korea, Republic of
  • The Catholic University of Korea Yeouido St. Mary's Hospital
    Seoul, Korea, Republic of
  • Ulsan University Hospital
    Ulsan, Korea, Republic of
  • The Christie NHS Foundation Trust
    Manchester, Greater Manchester, United Kingdom
  • Southampton General Hospital
    Southampton, Hampshire, United Kingdom
  • North Staffs Royal Infirmary
    Stoke-on-Trent, Staffordshire, United Kingdom
  • Beatson West of Scotland Cancer Centre
    Glasgow, Strathclyde, United Kingdom
  • New Cross Hospital
    Wolverhampton, West Midlands, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2011 to primary completion in Jan 2014, 26 months.

Results were first posted in Feb 2016, 2 years after primary completion. A results delay was requested in Oct 2015.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 26 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2012
First posted
Feb 8, 2012
StartActual
Nov 2011
Primary completionActual
Jan 21, 2014
CompletionActual
Jun 27, 2015
Results delay requested
Oct 5, 2015
Results first posted
Feb 18, 2016
Last update
Sep 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01529112
Lead sponsor
Eisai Inc.
Collaborators
Quintiles, Inc.
Responsible party
Sponsor
First posted
Feb 8, 2012
Start date
Nov 2011
Primary completion
Jan 21, 2014
Completion
Jun 27, 2015
Results posted
Feb 18, 2016
Last update
Sep 26, 2017

Study contacts

Harish Dave
study director · PharmaBio Development Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion